Solasia Pharma K.K. provided consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company expects revenue in the range of ¥1,000 million to ¥1,800 million, operating loss in the range of ¥1,150 million to ¥350 million, loss in the range of ¥1,150 million to ¥350 million, basic loss per share in the range of ¥6.85 to ¥2.08.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
26 JPY | +4.00% | +4.00% | -42.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.22% | 30.07M | |
-4.65% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023